ESMO 2018 | Telotristat in the management of NET-related carcinoid syndrome diarrhea

Name: Telotristat in the management of NET-related carcinoid syndrome diarrhea
Uploaded: 2019-01-18T18:26:38.000Z
Duration: 4 min 5 s

Rocio Garcia-Carbonero • 18 Jan 2019

ESMO 2018

Neuroendocrine Tumor Telotristat

TELECAST TELESTAR

The role of telotristat ethyl in patients with neuroendocrine tumors (NETs) and carcinoid syndrome diarrhoea has been evaluated in a recdent meta-analysis of the TELESTAR (NCT01677910) and TELECAST (NCT02063659) trials. Here, Rocio Garcia-Carbonero, MD, PhD, of the University Hospital of 12 de Octubre, Madrid, Spain, discusses the meta-analysis of these studies, highlighting the beneficial effects of diarrhoea alleviation in these patients. Dr Garcia-Carbonero speaks from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, and suggests the need to conduct long-term follow-up studies to address further potential side effects, such as carcinoid heart disease and fibrosis.